Trial Profile
The Effects of OMACOR on the LDL Sub-Fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Hyperlipoproteinaemia type IIb
- Focus Therapeutic Use
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 07 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Aug 2009 Actual initiation date (1 Jul 2009) added as reported by ClinicalTrials.gov.